In summer 2026, scientists at the University of Oxford and University College London plan to begin a first-of-its-kind ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

The Lung Cancer Research Foundation® (LCRF) recently awarded five new research grants in the following areas: three LCRF ...

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer ...

Belfast-based biotech company Biomarx has raised £700,000 in pre-seed funding to progress the development of a diagnostics ...

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

Investing.com -- Bayer’s drug sevabertinib has received Breakthrough Therapy Designation from both the U.S. Food and Drug Administration and China’s Center for Drug Evaluation for first-line treatment ...

Bayer received significant designations in the U.S. and China for its sevabertinib lung-cancer treatment.

Multidimensional intervention for patients with lung cancer incorporates rehabilitation, psychosocial support, nutrition guidance, health promotion, and safety surveillance. Multidimensional ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...